Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Evelyn Nietfeld

Nurse Practitioner Maple Grove, MN Nurse Practitioner

NPI 1477644235 CMS profile 10827346

9645 Grove Cir N Ste 200, Maple Grove, MN 55369

Open in the dashboard

General payments

$5,035

94 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Evelyn Nietfeld of Maple Grove, MN is reported in the CMS Open Payments database as having received $5,035 across 94 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $919 22
2024 General $1,705 27
2023 General $1,074 16
2022 General $816 17
2021 General $520 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Evelyn Nietfeld
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Evelyn Nietfeld were reported at $919. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Evelyn Nietfeld Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $520 $135 $40–$426 $132
2022 $816 $152 $48–$470 $149
2023 $1,074 $166 $54–$529 $160
2024 $1,705 $173 $55–$556 $164
2025 $919 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $913 18 payments
  2. Saluda Medical Americas, Inc. $822 9 payments
  3. SPR Therapeutics, Inc $679 7 payments
  4. Nevro Corp. $628 11 payments
  5. Medtronic, Inc. $459 12 payments
  6. Abbott Laboratories $423 11 payments
  7. Nalu Medical, Inc. $257 3 payments
  8. Vertos Medical, Inc. $176 3 payments
  9. BIOTRONIK NRO, Inc. $171 5 payments
  10. SI-BONE, Inc. $139 1 payment
  11. Other $368 14 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,995 93 payments
  2. Education $40 1 payment
Products named General payments · program years 2021–2025
  1. SPRINT PNS System $679 7 payments
  2. Evoke SCS $494 4 payments
  3. Omnia $387 7 payments
  4. INTELLIS ADAPTIVESTIM $372 9 payments
  5. Evoke $328 5 payments
  6. WaveWriter Alpha Prime 16 $291 4 payments
  7. Nalu Neurostimulation System $257 3 payments
  8. Senza $241 4 payments
  9. Intracept $201 3 payments
  10. PROCLAIM $190 5 payments
  11. Other $1,511 47 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,860

Median for Nurse Practitioner: 389

Drug cost

$160,563

Median for Nurse Practitioner: $21,885

Branded share of claims

40%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 54 $38,443
Oxycontin Oxycodone Hcl Brand 60 $24,403
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 27 $22,467
Buprenorphine Generic 52 $14,084
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 402 $10,995
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 39 $10,360
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 365 $7,354
Gabapentin Generic 233 $5,326
Oxycodone Hcl Generic 313 $4,019
Morphine Sulfate Er Morphine Sulfate Brand 172 $3,709

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$64,810

Medicare's payments for the services billed

Medicare patients

179

Average age 69

Services billed

847

123 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 66%
Depression 48%
Diabetes 26%
Chronic kidney disease 26%
Ischemic heart disease 25%
Osteoporosis 20%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

94 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record